Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Follicular 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

pembrolizumab 42Carboplatin 38Cisplatin 34Paclitaxel 27Pemetrexed 23Gemcitabine 23Nivolumab 22Dexamethasone 17Ipilimumab 16Rituximab 15Fluorouracil 14Capecitabine 14Docetaxel 13trastuzumab deruxtecan 12durvalumab 12atezolizumab 12Cyclophosphamide 12Trastuzumab 11Lenalidomide 11olaparib 10130-nm albumin-bound paclitaxel 10Prednisone 9venetoclax 8daratumumab 8Oxaliplatin 8Cytarabine 8Bortezomib 8Bevacizumab 8zanubrutinib 7Vinorelbine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Has announcements × duvelisib × Clear all
NCT02204982 2023-09-28

DYNAMO + R

SecuraBio

Phase 3 Terminated
13 enrolled 10 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Hereditary Sensory and Autonomic Neuropathies

NCT02004522 2023-09-21

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

SecuraBio

Phase 3 Completed
319 enrolled 18 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡